Context

  • Product: Injectable chemotherapeutic with orphan designation for pancreatic cancer
  • Patients: Advanced, previously untreated, metastatic pancreatic cancer – a severe illness with very short life expectancy

The Challenge

  • Product efficacy clearly proven in randomised trials, significantly extending survival versus standard of care
  • Need to emphasise the importance of the survival gain relative to the poor prognosis of the condition

Our Solution

Outcome

  • Proportional shortfall results cited by European payers in decisions relating to the relative benefit of the product